8-K
false000089394900008939492022-04-282022-04-28

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2022

 

 

Mednax, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Florida

001-12111

26-3667538

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1301 Concord Terrace

 

Sunrise, Florida

 

33323

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 954 384-0175

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $.01 per share

 

MD

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 2.02 Results of Operations and Financial Condition.

On April 28, 2022, Mednax, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months ended March 31, 2022 (the “First Quarter Release”). A copy of the First Quarter Release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Current Report by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” with the Securities and Exchange Commission nor incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Index

 

99.1— Press Release of Mednax, Inc. dated April 28, 2022.

104 — Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Mednax, Inc.

 

 

 

 

Date:

April 28, 2022

By:

/s/ C. Marc Richards

 

 

 

C. Marc Richards
Chief Financial Officer

 


EX-99.1

 

 

https://cdn.kscope.io/b023f62cf22c9490eaa04ba39a1d3cba-img163251054_0.jpg 

 

FOR MORE INFORMATION:

Charles Lynch

Senior Vice President, Finance and Strategy

954-384-0175, x 5692

charles_lynch@mednax.com

 

FOR IMMEDIATE RELEASE

 

Mednax Reports First Quarter Results

 

FORT LAUDERDALE, Fla., April 28, 2022 - Mednax, Inc. (NYSE: MD), whose affiliated practices operate as Pediatrix® Medical Group, the nation’s leading provider of highly specialized health care for women, children and babies, today reported a loss from continuing operations of $0.25 per share for the three months ended March 31, 2022. Results from continuing operations include a pretax loss on early extinguishment of debt of $57 million. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.33.

 

For the 2022 first quarter, Mednax reported the following results from continuing operations:

 

Net revenue of $482 million;
Loss from continuing operations of $21 million; and
Adjusted EBITDA of $51 million.

 

“Our bottom line results were in line with our expectations and reflect continued patient volume growth,” said Mark S. Ordan, Chief Executive Officer of Mednax. “Our financial focus remains on increasing the efficiency of our support services and on growth in and around our core. Most important for the benefit of all our stakeholders is that we do all we prudently can to show support and care for our world-class affiliated clinicians. They are the heart and soul of Pediatrix.”

 

Operating Results from Continuing Operations – Three Months Ended March 31, 2022

 

Mednax’s net revenue for the three months ended March 31, 2022 was $482.2 million, compared to $446.8 million for the prior-year period. Mednax’s revenue growth was driven by net acquisition activity, complemented by an overall same-unit revenue increase of 1.3 percent.

 

Same-unit revenue attributable to patient volume increased by 3.2 percent for the 2022 first quarter as compared to the prior-year period with growth across all our service lines. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months ended March 31, 2022. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)

 

 


 



 

Three Months Ended
March 31, 2022

Hospital-based patient services

 

3.3%

Office-based patient services

 

4.8%

 

 

 

Neonatology services
(within hospital-based services):

 

 

Total births

 

3.9%

Neonatal intensive care unit (NICU) days

 

2.3%

 

Same-unit revenue from net reimbursement-related factors declined by 1.9 percent for the 2022 first quarter as compared to the prior-year period. This net decrease primarily reflects timing of certain revenue cycle management transition activities, partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act and increases in contract and administrative fees. The percentage of services reimbursed by commercial and other non-government payors was relatively unchanged for the year over year period. During the 2022 first quarter, the Company recorded $10.4 million of miscellaneous revenue from funds received under the CARES Act compared to $7.7 million in the prior year, which increased the Company’s same-unit revenue from net reimbursement-related factors by 0.6 percent during the three months ended March 31, 2022.

 

For the 2022 first quarter, practice salaries and benefits expense was $343.2 million, compared to $319.0 million for the prior-year period. This increase primarily reflects acquisitions completed over the past year.

 

For the 2022 first quarter, general and administrative expenses were $61.3 million, as compared to $66.5 million for the prior-year period. The net decrease of $5.2 million is primarily related to lower professional fees, including legal fees, as well as a net savings in revenue cycle management expenses.

 

For the first quarter of 2022, transformational and restructuring related expenses totaled $1.4 million, compared to $4.9 million for the fourth quarter of 2021. This decline primarily reflects lower expenses related to third-party consulting services compared to the prior year.

 

Adjusted EBITDA from continuing operations, which is defined as earnings from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses and also excludes loss on the early extinguishment of debt, was $50.7 million for the 2022 first quarter, compared to $45.5 million for the prior-year period. Funds received from the provider relief fund established by the CARES Act favorably impacted Adjusted EBITDA by approximately $6.2 million for the first quarter of 2022, compared to a favorable impact of $4.6 million in the prior year period.

 

Depreciation and amortization expense was $8.8 million for the first quarter of 2022 compared to $8.0 million for the first quarter of 2021.

 

Investment and other income was $0.9 million for the first quarter of 2022, compared to $6.0 million for the first quarter of 2021. This decrease primarily reflects the reimbursement received in the prior year period related to the transition services being provided to the buyers of the Company’s former anesthesiology and radiology medical groups.

 

During the first quarter of 2022, Mednax issued $400 million in 5.375% Senior Notes due 2030, the proceeds of which were used, together with a new $450 million revolving credit facility, a new $250 million term A loan and cash on hand, to redeem its $1.0 billion in outstanding principle amount of 6.25% Senior Notes due 2027 and pay related fees and expenses. For the 2022 first quarter, loss on early extinguishment of debt of $57.0 million related primarily to the call premium on the Senior Notes due 2027 as well as the write off of

 


 

deferred debt costs. Loss on early extinguishment of debt was $14.5 million for the 2021 first quarter and was related to the redemption of the Company’s $750.0 million in Senior Notes due 2023.

 

Interest expense was $11.8 million for the first quarter of 2022 compared to $17.6 million for the first quarter of 2021. This decrease of $5.8 million primarily reflects the net decrease in interest expense on the Company’s senior notes.

 

Mednax generated a loss from continuing operations of $20.9 million, or $0.25 per diluted share, for the 2022 first quarter, based on a weighted average 85.4 million shares outstanding. This compares with income from continuing operations of $5.4 million, or $0.06 per diluted share, for the 2021 first quarter, based on a weighted average 85.5 million shares outstanding.

 

For the first quarter of 2022, Mednax reported Adjusted EPS from continuing operations of $0.33, compared to $0.24 for the first quarter of 2021. For these periods, Adjusted EPS from continuing operations is defined as diluted income from continuing operations per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, and discrete tax events, and for both periods also excludes the impact from the loss on early extinguishment of debt. Funds received from the provider relief fund established by the CARES Act favorably impacted Adjusted EPS by $0.07 for the 2022 first quarter, compared to a favorable impact of $0.05 for the first quarter of 2021.

 

Financial Position and Cash Flow – Continuing Operations

 

Mednax had cash and cash equivalents of $7 million at March 31, 2022, compared to $387 million on December 31, 2021, and net accounts receivable were $318 million. As previously disclosed, during the first quarter of 2022 the Company used cash on hand, together with proceeds from the new issuance of debt, to redeem its $1.0 billion in outstanding principal amount of 6.25% Senior Notes due 2027 and pay related fees and expenses.

 

During the first quarter of 2022, Mednax used cash of $89.9 million to fund continuing operations, compared to a use of $98.9 million during the first quarter of 2021. Mednax typically uses cash during the first quarter of each year as it pays incentive compensation, principally to its affiliated physicians, and employee benefit plan matching contributions that were accrued during the prior year. Additionally, during the first quarter of 2022, the Company used $25.7 million to fund acquisitions and $7.1 million to fund capital expenditures.

 

At March 31, 2022, Mednax had total debt outstanding of $799 million, consisting of its $400 million in 5.375% Senior Notes due 2030; $250 million in borrowings under its Term A Loan; and $149 million in borrowings under its revolving line of credit.

 

Non-GAAP Measures

 

A reconciliation of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three months ended March 31, 2022 and 2021 is provided in the financial tables of this press release.

 

Earnings Conference Call

 

Mednax, Inc. will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company’s Website, www.mednax.com. A telephone

 


 

replay of the conference call will be available from 12:45 p.m. ET today through midnight ET May 12, 2022 by dialing 866.207.1041, access Code 7323641. The replay will also be available at www.mednax.com.

 

ABOUT MEDNAX

 

Mednax, Inc. is a national medical group comprised of the nation’s leading providers of physician services practicing under the Pediatrix® brand. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by 18 pediatric subspecialties, as well as a newly expanded area of primary and urgent care clinics. The group’s high-quality, evidence-based care is bolstered by investments in research, education, quality-improvement and safety initiatives. The company was founded in 1979 as a single affiliated neonatology practice and today provides its highly focused and often critical care services through more than 4,700 affiliated physicians and other clinicians in 38 states and Puerto Rico. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn, Twitter and the Pediatrix blog. Mednax investment information can be found at www.mednax.com/investors.

 

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the impact of surprise billing legislation; the Company’s ability to comply with the terms of its debt financing arrangements; the Company’s transition to a third-party revenue cycle management provider; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

 

###

 

 

 

 


 

 

Mednax, Inc.

Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

 

 

2022

 

 

2021

 

Net revenue

 

$

482,229

 

 

$

446,753

 

Operating expenses:

 

 

 

 

 

 

Practice salaries and benefits

 

 

343,155

 

 

 

319,012

 

Practice supplies and other operating expenses

 

 

28,489

 

 

 

22,212

 

General and administrative expenses

 

 

61,287

 

 

 

66,516

 

Depreciation and amortization

 

 

8,769

 

 

 

8,031

 

Transformational and restructuring related expenses

 

 

1,421

 

 

 

4,878

 

Total operating expenses

 

 

443,121

 

 

 

420,649

 

Income from operations

 

 

39,108

 

 

 

26,104

 

Investment and other income

 

 

875

 

 

 

5,967

 

Interest expense

 

 

(11,818

)

 

 

(17,645

)

Loss on early extinguishment of debt

 

 

(57,016

)

 

 

(14,532

)

Equity in earnings of unconsolidated affiliate

 

 

505

 

 

 

495

 

Total non-operating expenses

 

 

(67,454

)

 

 

(25,715

)

(Loss) income from continuing operations before income taxes

 

 

(28,346

)

 

 

389

 

Income tax benefit

 

 

7,401

 

 

 

4,955

 

(Loss) income from continuing operations

 

 

(20,945

)

 

 

5,344

 

(Loss) income from discontinued operations, net of tax

 

 

(247

)

 

 

12,290

 

Net (loss) income

 

 

(21,192

)

 

 

17,634

 

Net loss attributable to noncontrolling interest

 

 

4

 

 

 

8

 

Net (loss) income attributable to Mednax, Inc.

 

$

(21,188

)

 

$

17,642

 

Per common and common equivalent share data (diluted):

 

 

 

 

 

 

(Loss) income from continuing operations

 

$

(0.25

)

 

$

0.06

 

Income from discontinued operations

 

$

 

 

$

0.15

 

Net (loss) income attributable to Mednax, Inc.

 

$

(0.25

)

 

$

0.21

 

Weighted average common shares

 

 

85,405

 

 

 

85,491

 

 

 

 

 

 

 

 

 

 

 


 

 

Mednax, Inc.

Reconciliation of Income (Loss) from Continuing Operations

to Adjusted EBITDA from Continuing Operations Attributable to Mednax, Inc.

(in thousands)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

 

 

2022

 

 

2021

 

(Loss) income from continuing operations attributable to Mednax, Inc.

 

$

(20,941

)

 

$

5,352

 

Interest expense

 

 

11,818

 

 

 

17,645

 

Loss on early extinguishment of debt

 

 

57,016

 

 

 

14,532

 

Income tax benefit

 

 

(7,401

)

 

 

(4,955

)

Depreciation and amortization expense

 

 

8,769

 

 

 

8,031

 

Transformational and restructuring related expenses

 

 

1,421

 

 

 

4,878

 

Adjusted EBITDA from continuing operations attributable to Mednax, Inc.

 

$

50,682

 

 

$

45,483

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

Mednax, Inc.

Reconciliation of Diluted Income (Loss) from Continuing Operations per Share

to Adjusted Income from Continuing Operations per Diluted Share (“Adjusted EPS”)

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

 

 

2022

 

 

2021

 

Weighted average diluted shares outstanding

 

85,405

 

 

85,491

 

(Loss) income from continuing operations and diluted income from continuing operations per share attributable to Mednax, Inc.

 

$

(20,941

)

 

$

(0.25

)

 

$

5,352

 

 

$

0.06

 

Adjustments (1):

 

 

 

 

 

 

 

 

 

 

 

 

Amortization (net of tax of $541 and $890)

 

 

1,621

 

 

 

0.02

 

 

 

2,672

 

 

 

0.03

 

Stock-based compensation (net of tax of $1,109 and $929)

 

 

3,326

 

 

 

0.04

 

 

 

2,788

 

 

 

0.03

 

Transformational and restructuring expenses (net of tax of $355 and $1,219)

 

 

1,066

 

 

 

0.01

 

 

 

3,659

 

 

 

0.04

 

Loss on early extinguishment of debt (net of tax of $14,254 and $3,633)

 

 

42,762

 

 

 

0.50

 

 

 

10,899

 

 

 

0.13

 

Net impact from discrete tax events

 

 

492

 

 

 

0.01

 

 

 

(5,067

)

 

 

(0.05

)

Adjusted income and diluted EPS from continuing operations attributable to Mednax, Inc.

 

$

28,326

 

 

$

0.33

 

 

$

20,303

 

 

$

0.24

 

 

(1)
A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended March 31, 2022 and 2021.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Mednax, Inc.

Balance Sheet Highlights

(in thousands)

(Unaudited)

 



 

As of
March 31, 2022

 

 

As of
December 31, 2021

 

Assets:

 



 

 



 

Cash and cash equivalents

 

$

7,179

 

 

$

387,391

 

Investments

 

 

89,576

 

 

 

99,715

 

Accounts receivable, net

 

 

317,619

 

 

 

301,775

 

Other current assets

 

 

25,403

 

 

 

51,683

 

Intangible assets, net

 

 

21,050

 

 

 

21,565

 

Operating and finance lease right-of-use assets

 

 

66,055

 

 

 

65,461

 

Goodwill, other assets, property and equipment

 

 

1,814,094

 

 

 

1,794,956

 

Total assets

 

$

2,340,976

 

 

$

2,722,546

 

Liabilites and equity:

 



 

 



 

Accounts payable and accrued expenses

 

$

232,089

 

 

$

394,118

 

Total debt, net

 

 

807,334

 

 

 

1,004,748

 

Operating lease liabilities

 

 

61,874

 

 

 

61,080

 

Other liabilities

 

 

362,603

 

 

 

365,908

 

Total liabilities

 

 

1,463,900

 

 

 

1,825,854

 

Total equity

 

 

877,076

 

 

 

896,692

 

Total liabilities and equity

 

$

2,340,976

 

 

$

2,722,546